Drug Profile
EF 6265
Latest Information Update: 04 Dec 2006
Price :
$50
*
At a glance
- Originator Meiji Seika Kaisha
- Class Antithrombotics
- Mechanism of Action Carboxypeptidase U inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 06 Aug 2003 EF 6265 is available for licensing [www.meiji.co.jp]
- 06 Aug 2003 Preclinical trials in Thrombosis in Japan (unspecified route)